opakalim — Topline data
H2 2026
Dosing continues and topline data readout remains on timeline for the second half of 2026.Source filing
BHVN biotech catalysts & pipeline
BIOHAVEN LTD · Data as of 2026-10-25
Upcoming catalysts
taldefgrobep alfa — Topline data
H2 2026
Topline results for the Phase 2 proof-of-concept study are expected in the second half of 2026.Source filing
Vyglxia (troriluzole) — Filing acceptance
Q1 2027
The FDA communicated that it considers the resubmission a complete response to the November 4, 2025 action letter, and has assigned a user fee goal date in the first quarter of 2027.Source filing
BHV-1530 — Conference presentation
Oct 23–Oct 27
In July 2026, the Company announced that new data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, will be presented at the ESMO Congress 2026.Source filing